ABIOMED

Abiomed is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI cardiogenic shock patients are expected to significantly improve patient outcomes.

Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance

BOSTON--(BUSINESS WIRE)--Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (Nasdaq: ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardiogenic shock patients. The FDA has approved the on-label RECOVER IV randomized controlled trial (RCT) for AMI cardiogenic shock patients. RECOVER IV is a two-arm trial that will assess whether percutaneous coronary intervention (PCI), with Impella support initiated prior to t

FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

BOSTON--(BUSINESS WIRE)--TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery

TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio

Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.

Abiomed's (ABMD) Impella Favored by Latest Study Result

DANVERS, Mass.--(BUSINESS WIRE)--Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

The company's stock rose steadily throughout the month.

Why Shares of Abiomed Rose 18.4% in July

Abiomed, Inc. (NASDAQ:ABMD ) Q1 2023 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Brandon Vazquez - William Blair Marie Thibault - BTIG Pito Chickering - Deutsche Bank Chris Pasquale - Nephron Research Matt O'Brien - Piper Sandler Mike Polark - Wolfe Research Jayson Bedford - Raymond James Calvin Chu - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Abiomed FY '23 Q1 Earnings Call.

Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2023 Results - Earnings Call Transcript

Abiomed came in with another set of robust earnings yesterday, with double-digit growth from top to bottom. Earnings remain steady, however, the company exhibits the profitability features investors are paying a premium for.

Abiomed: Small Premium For Access To ~11% Normalized ROIC

Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.

Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down

Abiomed (ABMD) delivered earnings and revenue surprises of 15.74% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) Q1 Earnings Top Estimates

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces first quarter record revenue of $277 million, up 10% year over year, up 12% in constant currency.

ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*

Abiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abiomed (ABMD) Expected to Beat Earnings Estimates: Should You Buy?

Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Abiomed (ABMD) Keep the Earnings Surprise Streak Alive?

Edwards Lifesciences

The GF Score system from GuruFocus is a unique metric that takes into account a company's financial strength, profitability, growth, valuation and momentum to determine if the stock is likely to outperform. Those stocks with higher GF Scores generally produce higher returns than those with lower GF Scores, according to a backtesting study by GuruFocus.

2 Medical Device Stocks With Extremely High GF Scores

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to release financials and host conference call to discuss the results for the first quarter of the fiscal year 2023 on August 4, 2022.

Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification

Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to host investor call on heart failure opportunity with Impella 5.5 and Impella BTR heart pumps.

Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present (live) at the William Blair 42nd Annual Growth Stock Conference.

Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed will feature the most recent Impella research, technological advances aimed at improving AMICS patient outcomes at SCAI Scientific Sessions.

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Abiomed (ABMD) is a Top Growth Stock for the Long-Term

Abiomed, Inc. (NASDAQ:ABMD ) Q4 2022 Results Conference Call April 28, 2022 8:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Michael Minogue - President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Brandon Vazquez - William Blair & Company Danielle Antalffy - SVB Leerink Imron Zafar - Deutsche Bank Michael Polark - Wolfe Research Christopher Cooley - Stephens Inc Operator Hello, and a warm welcome to today's Abiomed Fiscal Year 2022 Fourth Quarter Earnings Call. My name is Emma, and I will be coordinating the call today.

Abiomed, Inc. (ABMD) CEO Michael Minogue on Q4 2022 Results - Earnings Call Transcript

Abiomed's (ABMD) strength in Impella product revenues drives its Q4 top line.

News for ABIOMED Stock (ABMD)